High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
It is another big week on the earnings front with a lots of big name companies reporting. This week could make or break the market. This week we have SpaceX, Advanced Micro Devices, Palantir Technologies, Sandisk, Uber Technologies, McDonald’s, Caterpillar, Merck & Company, Disney, Shopify and Arista Networks all reporting in what shapes as a busy and pivotal week for stocks.
Global pharmaceutical company Merck (NYSE:MRK) will be announcing earnings results this Tuesday before market hours. Here’s what investors should know.
The monthly jobs report comes out Friday. Before that, Elon Musk’s SpaceX will post its first earnings report as a listed company. Also reporting: Walt Disney; tech companies Palantir and Advanced Micro Devices; ride-sharing firms Uber and Lyft; private-equity firms Apollo, Carlyle and TPG; and fast-food chains McDonald's and Wendy’s.
Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.
Moderna posted a narrower per-share loss and higher revenue in its latest quarter, but shares were tumbling anyway. Moderna posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year. The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.
Shareholders of Organon & Co. (NYSE:OGN) approved the company’s proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting results announced during the meeting. The special meeting was convened solely to cons
Shares of Merck & Co., Inc. (MRK) rise 3,453% since 1990 thanks to institutional investors.
MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.
The daily medication is expected to be list-priced at $10.50 per pill. Here's what to know about Merck's new cholesterol drug Lipfendra.
Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.
Lipfendra, to be taken once a day, is designed to help lower cholesterol levels beyond what statins alone can achieve.
Merck & Co. is expected to announce its second-quarter earnings in August, and Wall Street forecasts a double-digit decline in its profits.
Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.
Stock Market Today: The Dow Jones index fell Monday, while tech futures rallied. Micron stock and Sandisk rebounded in premarket trading.
Merck stock is in a buy zone after hitting a new high. Fellow Dow stock JPMorgan Chase and Amphenol are both trading around entry points.
June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according to letters seen by Reuters.
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
Moderna shares were up more than 10% Friday after the biotech company revealed a new effort to make a treatment for autoimmune disorders and outlined several experimental drug projects that could help it diversify beyond Covid-19 vaccines in coming years.
Bio-Techne Corp. (NASDAQ:TECH) is one of the 9 Stocks Winning by Double Digits. Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors gobbled up shares following news that it is merging with pharmaceutical giant Merck for $11.3 billion. In a statement, Bio-Techne Corp. (NASDAQ:TECH) said […]
Find insight on Merck KGaA’s deal to buy Bio-Techne, GSK and more in the latest Market Talks covering the Health Care sector.
US stocks (^DJI, ^IXIC, ^GSPC) search for direction ahead of Thursday's session close, while Micron Technology (MU) holds onto gains following its massive earnings beat yesterday. Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the day's market moves, Big Tech stocks, and how Micron's stock gains may be impacting Apple (AAPL).
The proposed acquisition will be the company’s biggest deal in more than a decade and represents an early move by new CEO Kai Beckmann to bolster the business.
June 25 () - Merck KGaA has agreed to acquire biotech firm Bio-Techne Corp for $11.3 billion, the German science and healthcare firm said in a statement on Thursday.
Merck KGaA offered $73 a share in cash for Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier’s closing price Wednesday.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
